With a new high-tech 3D Brain-on-a-Chip technology Braingineering Technologies (BTech), a designated spin-off of the Luxembourg Centre for Systems Biomedicine (LCSB), supports pharmaceutical companies in the drug discovery and preclinical testing phase to increase their efficiency and the success rate of compounds that pass the clinical trials, i.e. enhanced relevance.
We focus on central nervous system (CNS) diseases: Parkinson’s disease, Alzheimer’s disease, and further diseases.
BTechs' Brain-on-the-Chip technology allows the pre-clinical testing of novel compounds in a human disease relevant model for their potential application for treatment of Parkinson’s disease.
New high-tech 3D Brain-on-a-Chip technology mimicking the human disease and complexity in the brain
Reduces animal testing as innovative alternative in vitro technology platform
Cost-effective service due to less required media usage with microfluidics devices
We guarantee high standards of data storage and security
While the focus of our service is on the above described pre-clinical drug testing, we also offer the possibility to conduct toxicology studies.
Additionally, we also see the potential of addressing other neurodegenerative disorders, several personalized medicine related applications and multi-organ-on-the chip approaches.
While the current focus of our service is on Parkinson’s disease we aim at extending this portfolio to other neurodegenerative diseases. In particular we are interested in Alzheimer’s disease (age associated neurodegeneration) and Batten’s disease (rare childhood neuro-degeneration).
One of the main limitations in neuroscience and in the modelling of neurodegenerative diseases is the lack of advanced experimental in vitro models that recapitulate the complexity of the human brain.